Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization-embryo transfer

被引:38
作者
Mitwally, Mohamed F. [1 ]
Diamond, Michael P. [2 ]
Abuzeid, Mostafa [3 ]
机构
[1] Univ Minnesota, Div Reprod Endocrinol & Infertil, Dept Obstet Gynecol & Womens Hlth, Minneapolis, MN USA
[2] Wayne State Univ, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, Detroit, MI USA
[3] Michigan State Univ, Dept Obstet & Gynecol, Div Reprod Endocrinol & Infertil, E Lansing, MI 48824 USA
关键词
IM-P(4); in vitro fertilization; luteal support; micronized vaginal progesterone; BIOIDENTICAL HORMONE-THERAPY; PROSPECTIVE RANDOMIZED-TRIAL; PHASE SUPPORT; CORPUS-LUTEUM; INVITRO FERTILIZATION; CRINONE; 8-PERCENT; IVF CYCLES; ENDOMETRIOSIS; INFERTILITY; GEL;
D O I
10.1016/j.fertnstert.2009.02.047
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objective: To study the outcome of IVF-ET in women who used vaginal P (vaginal P(4)) versus those who used P in oil via IM injection (IM-P(4)) for luteal support. Design: Retrospective cohort. Setting: Tertiary referral infertility center. Patient(s): A cohort of 544 women. Intervention(s): In 145 women, vaginal P(4) was used, while in 399 women, IM-P(4) was used for luteal support. Main Outcome Measure(S): The primary outcome was ongoing pregnancy rate. Secondary outcomes included other IVF-ET outcomes: rates of clinical pregnancy and pregnancy loss (chemical and miscarriage) and serum P levels during the luteal phase and early pregnancy. Result(s): Women who used vaginal P(4) for luteal support had ongoing pregnancy rates (odds ratio [OR], 1.0675; 95% confidence interval [CI], 0.7587-1.5020) and rates of total pregnancy loss (OR, 1.0775; 95% CI, 0.7383-1.5727) that were not statistically different from those who used IM-P(4). During the luteal phase, women who used vaginal P(4) had mean serum P levels that were not statistically different from those who used IM-P(4). However. during early pregnancy, mean P levels in pregnant women who used vaginal P(4) were statistically significantly higher. Conclusion(s): In women undergoing IVF-ET according to the GnRH agonist long protocol, luteal support with vaginal P(4) was associated with treatment outcomes that were no different from those associated with IM-P(4) luteal support. (Fertil Steril(R) 2010;93:554-69. (C)2010 by American Society for Reproductive Medicine.)
引用
收藏
页码:554 / 569
页数:16
相关论文
共 60 条
[1]  
Abate A., 1999, Clinical and Experimental Obstetrics and Gynecology, V26, P203
[2]  
Anserini P, 2001, Minerva Ginecol, V53, P297
[3]   A COMPARATIVE, RANDOMIZED STUDY OF 3 DIFFERENT PROGESTERONE SUPPORT OF THE LUTEAL-PHASE FOLLOWING IVF/ET PROGRAM [J].
ARTINI, PG ;
VOLPE, A ;
ANGIONI, S ;
GALASSI, MC ;
BATTAGLIA, C ;
GENAZZANI, AR .
JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 1995, 18 (01) :51-56
[4]   Progesterone receptor isoform A but not B is expressed in endometriosis [J].
Attia, GR ;
Zeitoun, K ;
Edwards, D ;
Johns, A ;
Carr, BR ;
Bulun, SE .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2000, 85 (08) :2897-2902
[5]   Bioidentical hormone therapy: a panacea that lacks supportive evidence [J].
Boothby, Lisa A. ;
Doering, Paul L. .
CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2008, 20 (04) :400-407
[6]   Acute eosinophilic pneumonia associated with intramuscular administration of progesterone as luteal phase support after IVF: Case report [J].
Bouckaert, Y ;
Robert, F ;
Englert, Y ;
De Backer, D ;
De Vuyst, P ;
Delbaere, A .
HUMAN REPRODUCTION, 2004, 19 (08) :1806-1810
[7]   Pituitary-ovarian dysfunction and endometriosis [J].
Cahill, DJ ;
Hull, MGR .
HUMAN REPRODUCTION UPDATE, 2000, 6 (01) :56-66
[8]   Embryo implantation [J].
Carson, DD ;
Bagchi, I ;
Dey, SK ;
Enders, AC ;
Fazleabas, AT ;
Lessey, BA ;
Yoshinaga, K .
DEVELOPMENTAL BIOLOGY, 2000, 223 (02) :217-237
[9]  
CASPER RF, 1979, SCIENCE, V205, P408, DOI 10.1126/science.377491
[10]  
Channing C P, 1980, Int Rev Physiol, V22, P117